News
Tofacitinib Slows Joint Damage in Rheumatoid Arthritis
Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
Your search for tofacitinib returned 7 results
Drugs in the Pipeline
Tofacitinib Effective in Phase 3 Psoriasis Retreatment Study
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
News
Promising Results for Xeljanz as Potential Psoriatic Arthritis Tx
Pfizer announced top-line results from the OPAL Beyond study, the second Phase 3 trial of Xeljanz (tofacitinib citrate) for the potential treatment of patients with active psoriatic arthritis (PsA).
News
Methotrexate Monotherapy, Combo Therapy Compared for RA
Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.
News
Tofacitinib Goes Head-to-Head with Adalimumab in RA Study
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
News
Xeljanz Approved for Rheumatoid Arthritis
Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.
News
Vaccination Recommendations for RA Patients on DMARD Therapy
Vaccination rates in patients with rheumatoid arthritis remain poor "despite the high rates of infectious disease-related morbidity and mortality," a review published in Clinical Opinion in Rheumatology has found.
